Ozempic-like weight loss drug Mounjaro launched in India - Details
Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management. Approved by CDSCO, it targets GIP and GLP-1 receptors, aiming to improve blood sugar control and aid in weight loss. Clinical trials showed significant results, underlining its potential in treating diabetes and obesity.
Eli Lilly has launched Mounjaro in India, a new once-weekly injectable drug for type 2 diabetes and weight management. Approved by CDSCO, it targets GIP and GLP-1 receptors, aiming to improve blood sugar control and aid in weight loss. Clinical trials showed significant results, underlining its potential in treating diabetes and obesity.
